The majority of deaths in HFPEF are cardiovascular deaths, comprising 51–60% of deaths in epidemiological studies and ~70% in clinical trials. Among cardiovascular deaths, sudden death and heart ...

Introduction: Heart failure with preserved ejection fraction (HFpEF) is a heterogenous clinical syndrome that accounts for nearly half of all heart failure cases world-wide. The pathophysiological ...

Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...

Trial inclusion criteria are heterogeneous and have changed as the understanding of HFpEF as a disease syndrome has evolved.26 Combinations of LVEF cut-offs, prior heart failure hospitalisation, ...

The Recent Advances and Ongoing Challenges in HFpEF virtual Heart House Roundtable will serve as a valuable forum to delve deep into these critical issues. Through interactive discussions, ...

SGLT2 inhibitors and mitochondrial antioxidants reversed this effect. While the study is incomplete and preliminary, its strength lies in introducing hiPSC-CMs as a tool for investigating HFpEF ...

Estimating left ventricular ejection fraction (LVEF) levels and predicting LVEF-based heart failure (HF) groups using deep learning and patient clinical profiles. HF groups were categorized based on ...

The findings also support advancing our HFpEF clinical program with HU6," said Jayson Dallas, MD, CEO of Rivus, in a company press release. HuMain-HFpEF was a phase IIa randomized double-blind trial.

“The findings also support advancing our HFpEF clinical program with HU6.” Roche is one high-profile entrant in the obesity space that has its own solution to retaining muscle. The Swiss ...